This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Jul 17;189(2):151-153.

doi: 10.1093/bjd/ljad111.

Rapid response of cutaneous lupus erythematosus to treatment with the type 1 interferon receptor antagonist anifrolumab

Claudia Günther¹

Affiliations

PMID: 37002783
DOI: 10.1093/bjd/ljad111

Editorial

Rapid response of cutaneous lupus erythematosus to treatment with the type 1 interferon receptor antagonist anifrolumab

Claudia Günther. Br J Dermatol. 2023.

. 2023 Jul 17;189(2):151-153.

doi: 10.1093/bjd/ljad111.

Author

Claudia Günther¹

Affiliation

¹ Department of Dermatology, University Medical Center Hospital TU Dresden, Dresden, Germany.

PMID: 37002783
DOI: 10.1093/bjd/ljad111

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest C.G. has received fees from AstraZeneca and GSK.

Comment on

Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers.
Carter LM, Wigston Z, Laws P, Vital EM. Carter LM, et al. Br J Dermatol. 2023 Jul 17;189(2):210-218. doi: 10.1093/bjd/ljad089. Br J Dermatol. 2023. PMID: 36944572

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems